{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:07:49Z","timestamp":1770890869334,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Hunan pharmaceutical company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s13318-018-0461-2","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T14:16:18Z","timestamp":1517321778000},"page":"405-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetics and Safety of Levetiracetam Extended-Release Tablets and Relative Bioavailability Compared with Immediate-Release Tablets in Healthy Chinese Subjects"],"prefix":"10.1007","volume":"43","author":[{"given":"Meng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunlin","family":"Zong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengzhe","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"461_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1528-1157.1975.tb04721.x","volume":"16","author":"WA Hauser","year":"1975","unstructured":"Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia. 1975;16:1\u201366.","journal-title":"Epilepsia."},{"key":"461_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","volume":"34","author":"WA Hauser","year":"1993","unstructured":"Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935\u20131984. Epilepsia. 1993;34:453\u201368.","journal-title":"Epilepsia."},{"key":"461_CR3","doi-asserted-by":"publisher","first-page":"9861","DOI":"10.1073\/pnas.0308208101","volume":"101","author":"BA Lynch","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"461_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/NDT.S2937","volume":"4","author":"B AbouKhalil","year":"2008","unstructured":"AbouKhalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008;4:507\u201323.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"461_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0014-2999(95)00436-O","volume":"286","author":"M Noyer","year":"1995","unstructured":"Noyer M, Gillard M, Matagne A, H\u00e9nichart JP, W\u00fclfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995;286:137\u201346.","journal-title":"Eur J Pharmacol"},{"key":"461_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1001\/archneur.59.12.1909","volume":"59","author":"YH Sohn","year":"2002","unstructured":"Sohn YH, Jung HY, Kaelin-Lang A, Hallett M. Effect of levetiracetam on rapid motor learning in humans. Arch Neurol. 2002;59:1909\u201312.","journal-title":"Arch Neurol"},{"key":"461_CR7","first-page":"467","volume":"5","author":"CM Ulloa","year":"2009","unstructured":"Ulloa CM, Towfigh A, Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatr Dis Treat. 2009;5:467\u201376.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"461_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1528-1167.2008.01817.x","volume":"50","author":"J Peltola","year":"2009","unstructured":"Peltola J, Coetzee C, Jim\u00e9nez F, Litovchenko T, Ramaratnam S, Zaslavaskiy L, Lu ZS, Sykes DM. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia. 2009;50:406\u201314.","journal-title":"Epilepsia."},{"key":"461_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eplepsyres.2009.02.001","volume":"84","author":"E Rouits","year":"2009","unstructured":"Rouits E, Burton I, Gu\u00e9nol\u00e9 E, Troenaru MM, Stockis A, Sargentini-Maier ML. Pharmacokinetics of levetiracetam ER 500\u00a0mg tablets. Epilepsy Res. 2009;84:224\u201331.","journal-title":"Epilepsy Res"},{"key":"461_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","volume":"85","author":"PN Patsalos","year":"2000","unstructured":"Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77\u201385.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"461_CR11","first-page":"397","volume":"69","author":"RY Sun","year":"2005","unstructured":"Sun RY, Cheng ZY, Zheng QS. Drug and statistics software (DAS). Am J Pharm Educ. 2005;69(3):397\u20138.","journal-title":"Am J Pharm Educ."},{"key":"461_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/pst.326","volume":"8","author":"J Hummel","year":"2009","unstructured":"Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat. 2009;8:38\u201349.","journal-title":"Pharm Stat."},{"issue":"5","key":"461_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2125.2006.02782.x","volume":"63","author":"Q Zhao","year":"2007","unstructured":"Zhao Q, Jiang J, Li XM, Lu Z, Hu P. Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. Br J Clin Pharmacol. 2007;63(5):614\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"461_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2460\/ajvr.76.8.719","volume":"76","author":"LB Boozer","year":"2015","unstructured":"Boozer LB, Platt SR, Haley AC, Linville AV, Kent M, Barron LE, Nie B, Arnold RD. Pharmacokinetic evaluation of immediate- and extended-release formulations of levetiracetam in dogs. Am J Vet Res. 2015;76:719\u201323.","journal-title":"Am J Vet Res"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-018-0461-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0461-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0461-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:28:40Z","timestamp":1659097720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-018-0461-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["461"],"URL":"https:\/\/doi.org\/10.1007\/s13318-018-0461-2","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]},"assertion":[{"value":"30 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study was supported by Hunan pharmaceutical company (Changde, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Meng Wang, Mengmeng Wang, Quanying Zhang, Shunlin Zong, and Chengzhe Lv declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Study protocols and the informed consent forms were approved by the independent ethics committee of the Second Affiliated Hospital of Soochow University (Suzhou, China).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Subjects provided written informed consent before study participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}